- Home
- FEBO vs AXDX Comparison
FEBO vs AXDX Comparison
Compare FEBO & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- AXDX
- Stock Information
- Founded
- FEBO 1993
- AXDX 1982
- Country
- FEBO Hong Kong
- AXDX United States
- Employees
- FEBO N/A
- AXDX N/A
- Industry
- FEBO
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- FEBO
- AXDX Industrials
- Exchange
- FEBO Nasdaq
- AXDX Nasdaq
- Market Cap
- FEBO 12.7M
- AXDX 13.7M
- IPO Year
- FEBO 2023
- AXDX 1996
- Fundamental
- Price
- FEBO $1.22
- AXDX $0.53
- Analyst Decision
- FEBO
- AXDX
- Analyst Count
- FEBO 0
- AXDX 0
- Target Price
- FEBO N/A
- AXDX N/A
- AVG Volume (30 Days)
- FEBO 11.8K
- AXDX 57.1K
- Earning Date
- FEBO 05-02-2025
- AXDX 05-07-2025
- Dividend Yield
- FEBO N/A
- AXDX N/A
- EPS Growth
- FEBO N/A
- AXDX N/A
- EPS
- FEBO N/A
- AXDX N/A
- Revenue
- FEBO $16,319,897.00
- AXDX $11,698,000.00
- Revenue This Year
- FEBO N/A
- AXDX $7.25
- Revenue Next Year
- FEBO N/A
- AXDX N/A
- P/E Ratio
- FEBO N/A
- AXDX N/A
- Revenue Growth
- FEBO 9.01
- AXDX N/A
- 52 Week Low
- FEBO $0.93
- AXDX $0.49
- 52 Week High
- FEBO $17.68
- AXDX $2.09
- Technical
- Relative Strength Index (RSI)
- FEBO 52.81
- AXDX 25.64
- Support Level
- FEBO $1.04
- AXDX $0.50
- Resistance Level
- FEBO $1.22
- AXDX $0.59
- Average True Range (ATR)
- FEBO 0.12
- AXDX 0.07
- MACD
- FEBO 0.01
- AXDX 0.01
- Stochastic Oscillator
- FEBO 62.07
- AXDX 19.10
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.